193 related articles for article (PubMed ID: 22148003)
1. Fatal rhabdomyolysis in a patient with liver cirrhosis after switching from simvastatin to fluvastatin.
Baek SD; Jang SJ; Park SE; Ok TJ; Leem J; Lee HS; Park SJ; Kim TH
J Korean Med Sci; 2011 Dec; 26(12):1634-7. PubMed ID: 22148003
[TBL] [Abstract][Full Text] [Related]
2. [Statin-induced rhabdomyolysis and renal failure: also with fluvastatine].
Lado Lado FL; Rodríguez Moreno C; Cinza Sajurjo S; Durán Parrondo C; Pazo Núñez M; Lois Pernas A; Masa Vázquez L
An Med Interna; 2004 May; 21(5):235-7. PubMed ID: 15176926
[TBL] [Abstract][Full Text] [Related]
3. Fluvastatin, rhabdomyolysis, and myotoxicity.
Murinson BB; Maragakis NJ; Jacobson TA
Mayo Clin Proc; 2008 Nov; 83(11):1296; author reply 1297. PubMed ID: 18990330
[No Abstract] [Full Text] [Related]
4. The HMG Co-A reductase inhibitors ('statins') and myotoxic effects.
S Afr Med J; 2002 Aug; 92(8):596-7. PubMed ID: 12244613
[No Abstract] [Full Text] [Related]
5. Fluvastatin-induced rhabdomyolysis.
Modi JR; Cratty MS
Ann Pharmacother; 2002 Dec; 36(12):1870-4. PubMed ID: 12452746
[TBL] [Abstract][Full Text] [Related]
6. Fluvastatin: efficacy and safety in reducing cardiac events.
Chan MY; Lee CH
Expert Opin Pharmacother; 2005 Sep; 6(11):1883-95. PubMed ID: 16144508
[TBL] [Abstract][Full Text] [Related]
7. Interaction of clopidogrel and statins in secondary prevention after cerebral ischaemia - a randomized, double-blind, double-dummy crossover study.
Siepmann T; Heinke D; Kepplinger J; Barlinn K; Gehrisch S; Grählert X; Schwanebeck U; Reichmann H; Puetz V; Bodechtel U; Gahn G
Br J Clin Pharmacol; 2014 Nov; 78(5):1058-66. PubMed ID: 24803100
[TBL] [Abstract][Full Text] [Related]
8. Meeting national cholesterol education goals in clinical practice--a comparison of lovastatin and fluvastatin in primary prevention.
Nash DT
Am J Cardiol; 1996 Sep; 78(6A):26-31. PubMed ID: 8875972
[TBL] [Abstract][Full Text] [Related]
9. Possible colchicine rhabdomyolysis in a fluvastatin-treated patient.
Atasoyu EM; Evrenkaya TR; Solmazgul E
Ann Pharmacother; 2005; 39(7-8):1368-9. PubMed ID: 15956236
[No Abstract] [Full Text] [Related]
10. [A Woman Experienced Severe Thrombocytopenia When Treated With Fluvastatin].
Potier A; Dony A; Crapsky A; Ferry O; Piney D; Dufay E
Therapie; 2015; 70(6):541-4. PubMed ID: 26238127
[TBL] [Abstract][Full Text] [Related]
11. Rhabdomyolysis and acute kidney injury secondary to concomitant use of fluvastatin and rapamycin in a renal transplant recipient.
Basic-Jukic N; Kes P; Bubic-Filipi L; Vranjican Z
Nephrol Dial Transplant; 2010 Jun; 25(6):2036; author reply 2036-7. PubMed ID: 20332417
[No Abstract] [Full Text] [Related]
12. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
13. Oral anticoagulant drug interactions with statins: case report of fluvastatin and review of the literature.
Andrus MR
Pharmacotherapy; 2004 Feb; 24(2):285-90. PubMed ID: 14998226
[TBL] [Abstract][Full Text] [Related]
14. Statin toxicity: a situation that mimics viral hepatitis.
Cokça F; Ozkan S; Nergisoglu G; Memikoglu O; Azap A
Int J Clin Pharmacol Ther; 2005 Nov; 43(11):543-5. PubMed ID: 16300170
[TBL] [Abstract][Full Text] [Related]
15. Effect of fluvastatin for safely lowering atherogenic lipids in renal transplant patients receiving cyclosporine.
Holdaas H; Hartmann A; Stenstrøm J; Dahl KJ; Borge M; Pfister P
Am J Cardiol; 1995 Jul; 76(2):102A-106A. PubMed ID: 7604781
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in the treatment of patients with hypercholesterolemia: a meta-analysis of clinical trials.
Kong SX; Crawford SY; Gandhi SK; Seeger JD; Schumock GT; Lam NP; Stubbings J; Schoen MD
Clin Ther; 1997; 19(4):778-97. PubMed ID: 9377621
[TBL] [Abstract][Full Text] [Related]
17. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study).
Jones P; Kafonek S; Laurora I; Hunninghake D
Am J Cardiol; 1998 Mar; 81(5):582-7. PubMed ID: 9514454
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy.
Rätz Bravo AE; Tchambaz L; Krähenbühl-Melcher A; Hess L; Schlienger RG; Krähenbühl S
Drug Saf; 2005; 28(3):263-75. PubMed ID: 15733030
[TBL] [Abstract][Full Text] [Related]
19. Fluvastatin in the first-line therapy of acute coronary syndrome: results of the multicenter, randomized, double-blind, placebo-controlled trial (the FACS-trial).
Ostadal P; Alan D; Vejvoda J; Kukacka J; Macek M; Hajek P; Mates M; Kvapil M; Kettner J; Wiendl M; Aschermann O; Slaby J; Holm F; Telekes P; Horak D; Blasko P; Zemanek D; Veselka J; Cepova J
Trials; 2010 May; 11():61. PubMed ID: 20500832
[TBL] [Abstract][Full Text] [Related]
20. A review of the lipid-related effects of fluvastatin.
Liberopoulos EN; Daskalopoulou SS; Mikhailidis DP; Wierzbicki AS; Elisaf MS
Curr Med Res Opin; 2005 Feb; 21(2):231-44. PubMed ID: 15801994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
